{
  "id": 13806234,
  "title": "Mirum Pharmaceuticals to share phase 3 LIVMARLI study results",
  "url": "https://urgent.news/2026/10/11/mirum-pharmaceuticals-to-share-phase-3-livmarli-study-results",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-11T21:04:31.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/mirum-pharmaceuticals-to-share-phase-3-livmarli-study-results-93CH-4942847"
  },
  "original_language": "en",
  "account": "Mirum Pharmaceuticals is set to reveal the results of its Phase 3 clinical study on Monday at 8:30 a.m. ET. The study, known as EXPAND, evaluates the effectiveness of LIVMARLI, a drug for treating pruritus in patients with rare liver diseases. To join the investor call, U.S. participants can dial +1 833 461 5787 while international callers should use +1 585 542 9983 with access code 486697901. The results will also be available on the company's website and can be accessed through a webcast. LIVMARLI is currently approved for treating Alagille syndrome and progressive familial intrahepatic cholestasis, but the study aims to expand its use for cholestatic pruritus in children with ultra-rare liver diseases. In addition to LIVMARLI, Mirum Pharmaceuticals' commercial portfolio includes ATEBRIOZ for fibrodysplasia ossificans progressiva, CHOLBAM for bile-acid synthesis disorders, and CTEXLI for cerebrotendinous xanthomatosis. The company's clinical-stage pipeline also includes drugs for primary sclerosing cholangitis, primary biliary cholangitis, chronic hepatitis delta virus, and Fragile X syndrome.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Seeking Alpha News",
        "title": "Mirum Pharmaceuticals to report Livmarli trial results Monday",
        "url": "https://urgent.news/2026/10/11/mirum-pharmaceuticals-to-report-livmarli-trial-results-monday",
        "published": "2026-10-11T21:49:11.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}